MDB Capital And Mayo Clinic Collaborate To Advance Anti-Senescence Platform
$MDBH
Finance: Consumer Services
Finance
MDB Capital And Mayo Clinic Collaborate To Advance Anti-Senescence Platform
Save time and jump to the most important pieces.
Addison, TX, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, will hold a conference call on Wednesday, November 15, 2023, at 4:30 p.m. Eastern Time to discuss its results for the third quarter ended September 30, 2023. A press release detailing these results will be issued prior to the call. Christopher Marlett, CEO and Co-Founder of MDB will lead the call and will be joined by other members of the management team to review recent developments, ongoing initiatives, anticipated 2024 milestone
Record date of July 22, 2024 set for allocation preferences Closing and trading expected on NASDAQ on or before August 15 Addison, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, today announces the record date, allocation preference, and expected timeline for the proposed offering for Invizyne Technologies, Inc. In February 2024, Invizyne – a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life and a subsidiary of MDB Capital Holdings – file
Transformative Innovations in MASH Diagnostics Dallas, Texas, July 09, 2024 (GLOBE NEWSWIRE) -- PatentVest, the first integrated IP intelligence strategy and law firm, recently published a whitepaper that presents strategic insights in the fields of Metabolic-Associated Steatohepatitis (MASH) biomarkers and Point of Care (PoC) kits for MASH diagnostics. This whitepaper serves as a valuable resource for stakeholders looking to navigate the complex and rapidly evolving landscape of these fields, offering guidance on capitalizing on innovation, collaboration, and IP protection to gain a competitive edge. "This rapid growing field is mainly driven by the recent Rezdiffra
ADDISON, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, today announced a collaboration through a patent and know-how agreement with Mayo Clinic to develop a small molecule anti-senescence platform. This collaboration aims to advance research in longevity and age-related disease prevention. Senescent cells, which are dysfunctional cells that have permanently stopped dividing, have been implicated in the aging process and the development of chronic low-grade inflammation. This chronic inflammation has been linked to a variety of age-related diseases, includ
DEF 14A - MDB Capital Holdings, LLC (0001934642) (Filer)
10-Q - MDB Capital Holdings, LLC (0001934642) (Filer)
8-K - MDB Capital Holdings, LLC (0001934642) (Filer)
Addison, Texas, June 20, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB Capital"), a public venture platform focused on launching category-leading deep technology companies, today announced the appointment of Daniel Torpey to its Board of Directors, effective June 17, 2024. With the addition of Torpey, the MDB Capital Board now comprises eight members. Torpey brings over 24 years of experience at Ernst & Young LLP (EY), where he currently serves as an Assurance Partner in the Forensic & Integrity Services practice. His expertise spans accounting, auditing, compliance, financial reporting, fraud detection, and corporate investigations. "Dan's breadth of kn
Record date of July 22, 2024 set for allocation preferencesClosing and trading expected on NASDAQ on or before August 15Addison, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, today announces the record date, allocation preference, and expected timeline for the proposed offering for Invizyne Technologies, Inc.In February 2024, Invizyne – a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life and a subsidiary of MDB Capital Holdings – filed its IPO registration stateme